Publish Ahead of Print

Original Article

Performance of various risk prediction models in a large lung cancer screening cohort in Gdańsk, Poland—a comparative study
Marcin Ostrowski, Franciszek Bińczyk, Tomasz Marjański, Robert Dziedzic, Sylwia Pisiak, Sylwia Małgorzewicz, Mariusz Adamek, Joanna Polańska, Witold Rzyman

Review Article

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Ana Casal-Mouriño, Alberto Ruano-Ravina, María Lorenzo-González, Ángeles Rodríguez-Martínez, Alexandra Giraldo-Osorio, Leonor Varela-Lema, Tara Pereiro-Brea, Juan Miguel Barros-Dios, Luis Valdés-Cuadrado, Mónica Pérez-Ríos
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Boris Duchemann, Jordi Remon, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput
Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
Francesco Passiglia, Valeria Cetoretta, Marco De Filippis, Valerio Napoli, Silvia Novello
Managing screening-detected subsolid nodules—the Asian perspective
Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee
Lung cancer screening: targeting the hard to reach—a review
Guido Van Hal, Paloma Diab Garcia
Evolving target volume concepts in locally advanced non-small cell lung cancer
Ursula Nestle, Cecile Le Pechoux, Dirk De Ruysscher
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Caroline Huynh, Logan A. Walsh, Jonathan D. Spicer
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer
Eric K. Singhi, Carl M. Gay
Mediastinal staging for non-small-cell lung cancer
Virginia Leiro-Fernández, Alberto Fernández-Villar
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Kenichi Suda, Tetsuya Mitsudomi
Screen-detected solid nodules: from detection of nodule to structured reporting
Mario Silva, Gianluca Milanese, Roberta E. Ledda, Ugo Pastorino, Nicola Sverzellati
Holding our breath: the promise of tissue-resident memory T cells in lung cancer
Claire Marceaux, Clare E. Weeden, Claire L. Gordon, Marie-Liesse Asselin-Labat
Prophylactic cranial irradiation in SCLC
Rafal Suwinski
Lung cancer screening: who pays? who receives?—the Chinese perspective
Yang Zhang, Haiquan Chen
Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury, Alexander Drilon
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo
Overcoming TKI resistance in fusion-driven NSCLC: New generation inhibitors and rationale for combination strategies
Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo
Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
Ana Karina Patané
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli
Controversies in the role of radiotherapy in pleural mesothelioma
Gerard G. Hanna, Thomas John, David L. Ball
Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question
Paul Van Houtte, Luigi Moretti, Florian Charlier, Martine Roelandts, Dirk Van Gestel
Should sublobar resection be offered for screening-detected lung nodules?
Alan D. L. Sihoe
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks
Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?
Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs
Immunotherapy in oncogene addicted non-small cell lung cancer
Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
Akira Hamada, Junichi Soh, Tetsuya Mitsudomi
Managing of screening-detected sub-solid nodules—a European perspective
Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo
Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
Olwen Leaman Alcibar, Ernest Nadal, Inmaculada Romero Palomar, Arturo Navarro-Martin
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
Roxana Reyes, Noemi Reguart
Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer
Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T. Leong, Daniel P. Steinfort
The radiologist’s role in lung cancer screening
Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel
Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
Lucyna Kepka, Joanna Socha
Induction treatment in patients with stage III non-small cell lung cancer
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal
Challenges in the target volume definition of lung cancer radiotherapy
Susan Mercieca, José S. A. Belderbos, Marcel van Herk
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti
Radiotherapy for thymic epithelial tumours: a review
Krisztian Süveg, Paul Martin Putora, Markus Joerger, Thomas Iseli, Galina Farina Fischer, Karlheinz Ammann, Markus Glatzer
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Ibiayi Dagogo-Jack, Lauren L. Ritterhouse